p53 expression, p21 expression and the apoptotic index in endometrioid endometrial adenocarcinoma

Histopathology

Volumn 35, Issue 3, 1999, Pages 221-229

  Burton, J L ^a   Stewart, R L ^a   Heatley, M K ^b   Royds, J A ^a   Wells, M ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Apoptosis; Endometrial cancer; Immunohistochemistry; p21; p53

Indexed keywords

DNA; PROTEIN P21; PROTEIN P53;

ADULT; AGED; APOPTOSIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION FUNCTION; ENDOMETRIUM CARCINOMA; FEMALE; GENE EXPRESSION REGULATION; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

AGED; AGED, 80 AND OVER; APOPTOSIS; CARCINOMA, ENDOMETRIOID; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LINEAR MODELS; MIDDLE AGED; STATISTICS, NONPARAMETRIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032861609     PISSN: 03090167     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2559.1999.00703.x     Document Type: Article

References (33)

1. Rose PG. Endometrial carcinoma. N. Engl. J. Med. 1996; 335; 640-649.
2. Hoffman K, Nekhlyudar L, Deligclisch L. Endometrial carcinoma in elderly women. Gynecol. Oncol. 1995; 58; 198-201.
3. dos Santos Silva Swerdlow AJ. Recent trends in incidence of and mortality from breast, ovarian and endometrial cancers in England and Wales and their relation to changing fertility and oral contraceptive use. Br. J. Cancer 1995; 72; 485-492.
4. Zaino RJ. Taking another look at endometrial carcinoma. Int. J. Gynecol. Pathol. 1996; 15; 10-17.
5. Porter PI, Gown AM, Kramp SG, Coltrera MD. Widespread p53 overexpression in human malignant tumours: an immunohistochemical study using methacarn-fixed, embedded tissue. Am. J. Pathol. 1992; 140; 145-153.
6. Kohler MF, Carney P, Dodge R et al. p53 overexpression in advanced-stage endometrial adenocarcinoma. Am. J. Obstet. Gynecol. 1996; 175; 1246-1252.
7. Stewart RL, Royds JA, Burton JL, Heatley MK, Wells M. Direct sequencing of the p53 gene shows absence of mutations in endometrial adenocarcinomas expressing p53 protein, Histopathology 1998; 33; 440-445.
8. Kohler MF, Berchuck A, Davidoff AM et al. Overexpression and mutation of p53 in edometrial carcinoma. Cancer Res. 1992; 52; 1622-1627.
9. Okamoto A, Sameshima Y, Yamada Y et al. Allelic loss of chromosome 17p and p53 mutations in human endometrial carcinoma of the uterus. Cancer Res. 1991; 51; 5632-5635.
10. Manek S, Wells M. The significance of alterations in p53 expression in gynaecological neoplasms. Curr. Opin. Obstet. Gynecol. 1996; 8; 52-55.
11. Yamauchi N, Sakamoto A, Uozaki H, Iihara K, Machinami R. Immunohistochemical analysis of endometrial adenocarcinoma for bcl-2 and p53 in relation to expression of sex steroid receptor and proliferative activity. Int. J. Gynecol. Pathol. 1996; 15; 202-208.
12. Inoue M, Okayama A, Fujita M et al. Clinicopathological characteristics of p53 overexpression in endometrial cancers. Int. J. Cancer 1994; 58; 14-19.
13. Inoue M, Fujita M, Enomoto T et al. Immunohistochemical analysis of p53 in gynecologic tumours. Ant. J. Clin. Pathol. 1994; 102; 665-670.
14. Save V, Sylander K, Hall PA. Why is p53 protein stabilised in neoplasia? Some answers but many more questions! J. Pathol. 1998; 184; 348-350.
15. Ito K, Sasano H, Matsunaga G et al. Correlations between p21 expression and clinicopathological findings, p53 gene and protein alterations, and survival in patients with endometrial carcinoma. J. Pathol. 1997; 183; 318-324.
16. Backe J, Gassel AM, Hauber K et al. p53 protein in endometrial cancer is related to proliferative activity and prognosis but not to expression of p21 protein. Int. J. Gynecol, Pathol. 1997; 16; 361-368.
17. Ioffe OB, Papadimitriou JC, Drachenberg CB. Correlation of proliferation indices, apoptosis, and related oncogene expression (bcl-2 and c-crbB-2) and p53 in proliferative, hyperplastic, and malignant endometrium, Hum. Pathol. 1998; 29; 1150-1159.
18. Heatley MK. The association between the apoptotic index and established prognostic parameters in endometrial adenocarcinoma. Histopathology 1995; 27; 469-472.
19. Kohlberger P, Gitsch G, Loesch A et al. p53 protein overexpression in early stage endometrial cancer. Gynecol, Oncol. 1996; 62; 213-217.
20. Caduff RF, Johnston CM, Svoboda-Newman SM, Poy EL, Merajver SD, Frank TS. Clinical and pathological significance of microsatellite instability in sporadic endometrial carcinoma. Am. J. Pathol. 1996; 148; 1671-1678.
21. Jones MW, Kounelis S, Hsu C et al. Prognostic value of p53 and K-ras-2 topographic genotyping in edometrial carcinoma: a clinicopathological and molecular comparison. Int. J. Gynecol. Pathol. 1997; 16; 354-360.
22. Nikaido T, Li SF, Khiozawa T, Fujil S. Coabnormal expression of cyclin D1 and p53 protein in human uterine endometrial carcinomas. Cancer 1996; 78; 1248-1253.
23. Yaginuma Y, Fujita M, Saitoh S, Hayakawa K, Kuzumaki N, Ishikawa M. Immunohistochemical analysis of ras oncogene product p21 in human endometrial carcinoma. Acta Histochem. 1993; 95; 23-29.
24. DiGiuseppe JA, Redston MS, Yeo CJ, Kern SE, Hruban RH. p53-independent expression of the cyclin-dependent kinase inhibitor p21 in pancreatic carcinoma. Am. J. Pathol. 1995; 147; 884-888.
25. WAFI/CIPI is heterogeneous and unrelated to proliferation index in human ovarian carcinoma. Int. J. Cancer 1995; 63; 611-615.
26. Shoji Y, Saegusa M, Takano Y, Ohbu M, Okayasu I. Correlation of apoptosis with tumour cell differentiation, progression, and HPV infection in cervical carcinoma. J. Clin. Pathol. 1996; 49; 134-138.
27. Michieli P, Chedid M, Lin D, Pierce JH, Mercer E, Givol D. Induction of WAF1/CIP1 by a p53-independent pathway. Cancer Res. 1994; 54; 3391-3395.
28. Wyllie AH. Apoptosis (The 1992 Frank Rose Memorial Lecture). Br. J. Cancer 1993; 67; 205-208.
29. Baas IO, Mulder J-WR, Offerhaus JA, Vogelstein B, Hamilton SR. An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J. Pathol. 1994; 172; 5-12.
30. Ito K, Watanabe K, Nasim S et al. Prognostic significance of p53 overexpression in endometrial cancer. Cancer Res. 1994; 54; 4667-4670.
31. Soong R, Knowles S, Williams KE, Hammond IG, Wysocki SJ, Iacopetta BJ. Overexpression of p53 protein is an independent prognostic indicator in human endometrial carcinoma. Br. J. Cancer 1996; 74; 562-567.
32. Yamauchi N, Sakamoto A, Uozaki H, Iihara K, Machinami R. Immunohistochemical analysis of endometrial adenocarcinoma for bel-2 and p53 In relation to sex steroid receptor and proliferative activity. Int. J. Gynecol. Pathol 1996; 15; 202-208.
33. Skomedal H, Kristensen GB, NesIand JM, Borresen-Dale A-L, Tropé C, Holm R. Tp53 alterations in relation to the cell cycle-associted proteins p21, cyclin DI, CDK4, RB, MDM2, and EGFR in cancers of the uterine corpus. J. Pathol. 1999; 187; 556-562.